AI for Pharmaceutical and Life Sciences Companies in Canada
Remolda helps Canadian pharmaceutical, biotech and medtech companies rank AI use cases in medical information, safety literature, regulatory documents and quality, with Health Canada guidance and privacy law in view. The AI Opportunity Audit costs $2,900 CAD + HST.
In short
- Price: AI Opportunity Audit $2,900 CAD + HST, fixed, two weeks; a six-week pilot at $9,800 builds one workflow.
- Scope: medical information responses, literature screening, regulatory document drafts and checks, SOP search and commercial analytics. Specialists sign off every output.
- Health Canada's pre-market guidance for machine learning-enabled medical devices, published April 1, 2026, covers Class II, III and IV devices and predetermined change control plans.
- Under PIPEDA, a company stays responsible for personal information it sends to an AI vendor for processing and must protect it by contract.
- Sessions and reports in English or French.
When life sciences teams call us
This page is for medical affairs, regulatory, quality and commercial leads in pharma, biotech and medtech companies operating in Canada. Typical situations:
- Medical information volumes are rising. Specialists answer similar questions from healthcare professionals every day, and response time matters.
- Literature screening takes analyst hours. The safety team reviews large volumes of abstracts to find the few that matter.
- A global AI tool is being rolled out. The Canadian affiliate needs to check privacy, language and data location before use.
- A medtech team is building a device with machine learning. Product leaders want the 2026 Health Canada guidance reflected in the development plan early.
- Staff use public AI tools with internal documents. Quality and compliance want an approved route.
What we automate for pharma and life sciences
Medical information responses. AI drafts replies to inquiries from approved standard response documents and product monographs, in English or French. A medical information specialist reviews and sends every reply.
Literature screening. AI screens abstracts and articles against your search criteria and flags those that may be relevant to safety. A pharmacovigilance specialist decides on every case.
Regulatory document drafting and checks. AI drafts sections from source documents and checks consistency of terms, numbers and references across a document set. Regulatory affairs owns the content. See document processing.
SOP and quality search. An internal assistant answers staff questions from current SOPs and work instructions and cites the controlled document.
Commercial and market access analytics. AI summarizes market data, formulary updates and field reports for brand teams. Analysts validate each summary.
Canadian rules that shape life sciences AI
Health Canada pre-market guidance for machine learning-enabled medical devices (April 1, 2026). It applies to manufacturers filing new or amended applications for Class II, III and IV devices. It introduces the predetermined change control plan, a way to pre-authorize planned model changes. Training data should be justified as representative of the Canadian population and clinical practice. For a medtech build, those expectations go into the data plan from the first sprint.
PIPEDA accountability for processors. Principle 4.1.3 keeps the company responsible for personal information transferred to a third party for processing and requires contractual protection. Every AI vendor contract is reviewed for this before data moves.
Quebec Law 25. Before personal information is communicated outside Québec, the company must conduct a privacy impact assessment and sign a written agreement. The same applies when an outside provider processes the data on its behalf.
OPC principles for generative AI. The federal and provincial privacy commissioners' nine principles include legal authority and consent, necessity and proportionality, accuracy and safeguards. They frame the privacy review of each use case.
US data, as context. Where a project touches US patient data, HIPAA applies to covered entities and business associates, and a written business associate contract is required.
Data location differs by vendor. Vendor selection compares Azure OpenAI, OpenAI, Claude and Amazon Bedrock on storage and processing location.
Which package fits
Most life sciences companies start with the AI Opportunity Audit, because use cases sit across several functions with different reviewers. The audit ends with a 12-month AI roadmap.
| Option | Price (CAD + HST) | Time | Best for |
|---|---|---|---|
| AI Readiness Review | $490 | 1 week | A Canadian affiliate that needs a fast position on a global tool |
| AI Opportunity Audit | $2,900 | 2 weeks | Ranked use cases across medical, regulatory, quality and commercial |
| AI Pilot Sprint | $9,800 | 6 weeks | One workflow, such as medical information drafts or literature screening |
Full scope of each package is on the pricing page.
How the work runs
The engagement follows the Remolda Cycle: Audit → Strategy → Implement → Empower → Evolve.
- Audit. Interviews with 6–10 people across medical affairs, regulatory, quality, safety, IT and privacy. We review process maps, volumes and approved tools.
- Strategy. Use cases ranked by value, effort and risk, each marked for GxP relevance and privacy review.
- Implement. A six-week pilot on one workflow, with non-personal or test data until quality and privacy approve live data.
- Empower. Training for the specialists who review AI output and a staff AI policy.
- Evolve. Performance checked against the acceptance criteria and the next use case planned.
In our experience quality and validation reviews usually set the pace. It depends on your quality system and on whether the process is GxP-relevant. For privacy obligations in depth, see AI compliance in Canada.
Typical scenario
Scenario: AI Patient Navigation and Scheduling in a Regional Health NetworkA worked scenario of how this engagement would run. It describes a typical situation with no named client.Read the scenarioFrequently asked questions
Where does AI help a pharma company first?
In document-heavy work with a specialist reviewer: drafting medical information responses from approved content, screening published literature for safety-relevant articles, checking consistency across regulatory documents and answering staff questions from SOPs. Each output is a draft that a qualified person approves.
What does Health Canada's machine learning device guidance cover?
The pre-market guidance for machine learning-enabled medical devices, published April 1, 2026, guides manufacturers filing new or amended applications for Class II, III and IV devices. It introduces predetermined change control plans and expects training data justified as representative of the Canadian population and clinical practice.
Does the guidance apply to AI we use internally?
It applies to medical devices that use machine learning to achieve their intended medical purpose. Internal tools for drafting, search or analytics are generally outside that definition; your regulatory affairs team confirms the classification for each tool.
Can we use AI with clinical trial or patient data?
Only with the legal basis, privacy review and vendor terms in place. PIPEDA keeps the company responsible for data sent to a processor. In Quebec, Law 25 requires a privacy impact assessment before personal information is communicated outside Québec. If US patient data is involved, HIPAA requires covered entities to have a business associate contract with vendors.
Do AI vendors train on our data?
Business plans from OpenAI and Anthropic state that business data is not used for training by default. Storage location differs by vendor: OpenAI offers storage at rest in Canada for eligible customers, and Amazon Bedrock keeps data at rest in Canada Central with inference in other regions.
How long does a pharma AI project take?
The audit is two weeks and a pilot is six weeks. In our experience quality and validation reviews usually set the calendar; it depends on your quality system and the GxP relevance of the process.
Sources
- Health Canada — Pre-market guidance for machine learning-enabled medical devices
- PIPEDA, Schedule 1, principle 4.1.3
- Act respecting the protection of personal information in the private sector (Quebec), s. 17
- Office of the Privacy Commissioner of Canada — Principles for responsible, trustworthy and privacy-protective generative AI technologies
- U.S. HHS — HIPAA covered entities and business associates
- OpenAI — Enterprise privacy and data residency
- AWS — Amazon Bedrock cross-Region inference in Canada
Facts checked:
Related services
Approach phases
Related insights
LLM Integration into Existing CRM and ERP Software in Canada: Architecture, Data Residency and Cost
Mitacs AI Advantage: Ottawa Commits $162M to 10,000 AI Work Placements
AI for Canadian Municipalities: Where It Works in 2026
Talk to an AI transformation consultant
A 30-minute call: you describe the situation, we tell you what to do first and what it would cost.
Book a 30-min call30 minutes. English or French.